<!--
HTML markup for chapter 7 tables which are rather long and complicated.
They had been created originally in MS Word resulting in hideous markup ....
Hazim Timimi, October 2022
-->

<style type="text/css">


.subhead, .footnote {
  font-size: 80%;
  font-weight: normal;
  margin-top: 0;
  padding-top: 0;
}

.red, .red a {
  color: #F21905; /* red text to show figure number */
}



.res_table {
  border-collapse: collapse;
  width: 100%;
  table-layout: fixed;
  width: 100%;
  margin-top: 1em;
  margin-bottom: 1em;
/* Next two lines to allow horizontal scrolling on narrow screens */
  display: block;
  overflow-x: auto;
}

/* light gray for odd rows */
.res_table tr:nth-child(odd) td {
  background-color: #F5F5F5;
}

.res_table td, .res_table th {
  border: 1px solid #ddd;
  padding: 8px;
  vertical-align: top;
}

.res_table th {
  padding: 12px;
  text-align: left;
  color: white;
}


</style>


<h3><span class="red">Table 7.1</span>&nbsp;An overview of progress in the development of TB diagnostics, August 2022</h3>

<table class="res_table">
  <tbody>
    <tr>
      <th style="background-color:#92C4E1;">Technologies in development</th>
      <th style="background-color:#4DA8DB;">On the market (Not yet evaluated by WHO)</th>
      <th style="background-color:#3B80A8;">Technologies under evaluation by WHO</th>
      <th style="background-color:#29465C;">Technologies endorsed by WHO</th>
    </tr>
    <tr>
      <td>
        <h4>Molecular detection of TB disease and drug resistance detection</h4>
        <ul>
          <li>Gendrive MTB/RIF ID, Epistem, UK</li>
          <li>TruDiagnosis, Akonni, USA</li>
          <li>INFINITIMTB Assay, AutoGenomics, USA</li>
          <li>FluoroType XDR-TB assay, Hain Lifescience, Germany</li>
          <li>MeltPro TB assay, Zeesan Biotech, China</li>
          <li>Q-POC, QuantuMDx, UK</li>
          <li>Truenat MTB-INH/MTB-FQ/MTB-BDQ, Molbio, India</li>
          <li>IRON qPCR Q-RFIA (preXDR-TB RT PCR), Bioneer, Republic of Korea</li>
          <li>STANDARD M MDR-TB; MTB/NTM; XDR-TB, SD Biosensor, Republic of Korea</li>
          <li>Mycobacterium Tuberculosis Rapid NAT Test Kit, Bao Ruiyuan Biotech (Beijing) Co., Ltd.  China</li>
          <li>MTB qSTAR test, LumiraDx, UK</li>
          <li>Genedrive system, Genedrive, UK</li>
        </ul>

        <h4>Aerosol capture technologies for TB disease detection</h4>
        <ul>
          <li>Face Mask Sampling, University of Leicester/FIND/42T, UK</li>
          <li>AveloCollect, Avelo, Switzerland</li>
        </ul>

        <h4>Interferon gamma release assays (IGRAs) for TB infection detection</h4>
          <ul>
            <li>IP-10 IGRA elisa/lateral flow, rBioPharm, Germany</li>
            <li>ichroma™ IGRA-TB, Boditech Med Inc., Republic of Korea</li>
            <li>T-Track(R) TB, Lophius Biosciences GmbH, Germany</li>
        </ul>

        <h4>Biomarker based assays for TB disease detection</h4>
          <ul>
            <li>PATHFAST-LAM, LSI Medience, Japan</li>
            <li>Salus FLOW TB Urine LAM Assay, Salus Discovery LLC, USA</li>
            <li>gLAMexpress, Mologic, UK</li>
            <li>SDB LAM assay, SD Biosensor, Republic of Korea</li>
            <li>TB Triage multiplex LFA, LUMC, The Netherlands &amp; the TB Triage consortium</li>
            <li>TB Molecular Bacterial Load Assay, University of St Andrews, U.K.</li>
            <li>T cell activation marker (TAM-TB) assay, Ludwig-Maximilians-University, Munich, Germany</li>
            <li>Xpert MTB Host response assay, Cepheid, USA</li>
            <li>RISK6 host response assay, QuantuMDx, UK</li>
            <li>BioMerieux ISIT-TB on BioFire FilmArray, France</li>
            <li>MARTI TB diagnostic test, MARTI TB diagnostics, South Africa</li>
            <li>PredictENDTB signature model, Research Center Borstel, Germany</li>
            <li>IRISA-TB, Antrum Biotech, South Africa</li>
            <li>Simoa SR-X, Quanterix, USA</li>
        </ul>

        <h4>Computer-aided detection (CAD) for digital chest radiography</h4>
          <ul>
            <li>T-Xnet, Artelius, India</li>
            <li>Dr CADx, Dr CADx, Zimbabwe</li>
            <li>OpenTB (provisional), Brazil</li>
          </ul>

        <h4>Other artificial-intelligence (AI)-based tools</h4>
          <ul><li>Digital stethoscope, AI Diagnostics, South Africa</li>
        </ul>
      </td>

      <td>
        <h4>Molecular detection of TB disease and/or drug resistance detection</h4>
          <ul>
            <li>iCubate System, iCubate, USA</li>
            <li>Genechip MDR test, Capital Bio, China</li>
            <li>EasyNAT TB Diagnostic kit, Ustar Biotechnologies, China</li>
            <li>AccuPower TB&amp;MDR Real Time PCR Kit, Bioneer, Republic of Korea</li>
            <li>AccuPower XDR-TB Real-Time PCR Kit-A, Bioneer, Republic of Korea</li>
            <li>AccuPower XDR-TB Real-Time PCR Kit-B, Bioneer, Republic of Korea</li>
            <li>MDR/MTB ELITe MGB&reg; Kit / ELITe InGenius&reg; platform, ELITech Group, Italy</li>
            <li>mfloDx MDR-TB, EMPE Diagnostics, Sweden</li>
            <li>Erythra-TB-KIT, Erythra, USA</li>
        </ul>
        <h4>Interferon gamma release assays (IGRAs) for TB infection detection</h4>
          <ul>
            <li>Quantiferon-Diasorin, USA</li>
            <li>Lioferon TB/LTBI, LIONEX Diagnostics &amp; Therapeutics GmbH, Germany</li>
            <li>VIDAS TB-IGRA, bioMérieux, France</li>
            <li>Advansure TB IGRA, LG chem, Republic of Korea</li>
            <li>Atlas NOVA assay, China</li>
        </ul>
        <h4>Computer-aided detection (CAD) for digital chest radiography</h4>
          <ul>
            <li>Genki, Deeptek, USA</li>
            <li>XrayAME, Epcon, Belgium</li>
            <li>InterRead DR Chest, InferVISION, China</li>
            <li>AXIR, RadiSen, Rep. of Korea</li>
            <li>JLK ver 1.1.03, Rep of Korea</li>
            <li>TiSepX TB ver 1, Rep of Korea</li>
            <li>JF CXR-1, JF HEALTHCARE, China</li>
            <li>ChestEye &amp;ChestLink, Oxipit, Lithuania</li>
            <li>Envisionit DEEP AI, South Africa</li>
            <li>Vuno Med&reg;-Chest X-ray, Rep of Korea</li>
        </ul>
      </td>

      <td>
        <h4>Culture-based drug susceptibility testing</h4>
          <ul>
            <li>SensititreTM MYCOTBI plate; ThermoFisher Scientific Inc., USA</li>
        </ul>
        <h4>Culture-free, targeted-sequencing solutions for detection of TB drug resistance</h4>
          <ul>
            <li>Deeplex&reg; Myc-TB, GenoScreen Innovative Genomic, France</li>
            <li>DeepChek&reg; TB, Advanced Biological Laboratories, France</li>
            <li>NanoTB, Oxford Nanopore Technologies, UK</li>
        </ul>
        <h4>Biomarker based assays for TB disease detection</h4>
          <ul>
            <li>Fujifilm SILVAMP TB LAM Assay, Fujifilm, Japan</li>
        </ul>
         <h4>Interferon gamma release assays (IGRAs) for TB infection detection</h4>
          <ul>
            <li>QIAReach QuantiFERON&reg;-TB, Qiagen, USA</li>
            <li>STANDARD E TB-Feron ELISA, SD Biosensor, Republic of Korea</li>
            <li>STANDARD F TB-Feron FIA, SD Biosensor, Republic of Korea</li>
        </ul>
      </td>

      <td>
         <h4>Molecular detection of TB disease and/or drug resistance</h4>
          <ul>
            <li>Xpert MTB/RIF, MTB/RIF Ultra and MTB/XDR, Cepheid, USA</li>
            <li>GenoType&reg; MTBDRplus, Hain Lifescience/Bruker, Germany</li>
            <li>Genoscholar&reg; NTM+MDRTB II; Nipro, Japan</li>
            <li>GenoType&reg; MTBDRsl, Hain Lifescience/Bruker, Germany</li>
            <li>TB LAMP, Eiken, Japan</li>
            <li>Truenat MTB, MTB Plus and MTB-RIF Dx assays, Molbio Diagnostics, India</li>
            <li>FluoroType MTB and MTBDR assays Hain Lifescience, Germany</li>
            <li>Abbott RealTime MTB and MTB RIF/INH on m2000sp and m2000rt systems, Abbott, USA</li>
            <li>BD Max MDR-TB, Becton Dickinson, USA</li>
            <li>Roche cobas&reg; MTB and MTB-RIF/INH on Cobas 6800/880 systems, Roche Diagnostics, Switzerland</li>
            <li>Genoscholar PZA TB II, Nipro, Japan</li>
        </ul>
        <h4>Interferon gamma release assays (IGRAs) for TB infection detection</h4>
          <ul>
            <li>T-SPOT.TB, Oxford Immunotec, UK</li>
            <li>QuantiFERON-TB Gold Plus (QFT-Plus), Qiagen, USA</li>
            <li>Wantai TB-IGRA, Wantai, China</li>
        </ul>

         <h4><i>Mycobacterium tuberculosis</i> antigen-based skin tests</h4>
          <ul>
            <li>>Diaskintest, JSC Generium, Russian Federation</li>
            <li>Cy-Tb skin test, Serum Institute of India, India</li>
            <li>C-TST, Anhui Zhifei Longcom Biopharmaceutical Co. Ltd, China</li>
        </ul>

         <h4>Culture-based technologies</h4>
          <ul>
            <li>Commercial liquid culture, DST systems and rapid speciation</li>
        </ul>

         <h4>Microscopy</h4>
          <ul>
            <li>Light and light-emitting diode microscopy (diagnosis and treatment monitoring)</li>
        </ul>

         <h4>Biomarker based assays</h4>
          <ul>
            <li>>Determine TB-LAM Ag, Abbott, USA</li>
        </ul>

         <h4>Computer-aided detection (CAD) for digital chest radiography</h4>
          <ul>
            <li>CAD4TB v6, Delft Imaging, Netherlands</li>
            <li>Lunit INSIGHT CXR (TB algorithm v4.9.0), Lunit, Republic of Korea</li>
            <li>qXR v2, qure.ai, India</li>
        </ul>
      </td>

    </tr>
  </tbody>
</table>






<h3><span class="red">Table 7.2</span>&nbsp;The global clinical development pipeline for new anti-TB drugs and drug regimens to treat TB disease, August 2022</h3>


<table class="res_table">
  <tbody>
    <tr>
      <th style="background-color:#92C4E1;">Phase I<sup>a</sup></th>
      <th style="background-color:#3B80A8;">Phase II<sup>a</sup></th>
      <th style="background-color:#29465C;">Phase III<sup>a</sup></th>
    </tr>
    <tr>
      <td><a href="https://clinicaltrials.gov/ct2/show/NCT04150224" data-sf-ec-immutable=""><strong>Macozinone</strong></a><sup>b</sup></td>
      <td><a href="https://clinicaltrials.gov/ct2/show/NCT04044001" data-sf-ec-immutable=""><strong>BTZ-043</strong></a><sup>b</sup></td>
      <td>Bedaquiline&ndash;delamanid&ndash;linezolid&ndash;levofloxacin&ndash;clofazimine (6-month oral regimen for RR-TB) or bedaquiline&ndash;delamanid&ndash;linezolid&ndash;clofazimine (6&ndash;9 month oral regimen for pre-XDR and XDR-TB) <a href="https://clinicaltrials.gov/ct2/show/NCT04062201" data-sf-ec-immutable=""><strong>(BEAT TB trial)</strong></a><sup>g</sup></td>
    </tr>
    <tr>
      <td><a href="https://clinicaltrials.gov/ct2/show/NCT04654143" data-sf-ec-immutable=""><strong>BVL-GSK098</strong></a><sup>b</sup></td>
      <td><a href="https://clinicaltrials.gov/ct2/show/NCT03557281" data-sf-ec-immutable=""><strong>GSK-3036656</strong></a><sup>b</sup></td>
      <td>Bedaquiline&ndash;pretomanid&ndash;moxifloxacin&ndash;pyrazinamide (BPaMZ) <a href="https://clinicaltrials.gov/ct2/show/NCT03338621" data-sf-ec-immutable=""><strong>(SimpliciTB trial)</strong></a></td>
    </tr>
    <tr>
      <td><a href="https://clinicaltrials.gov/ct2/show/NCT04472897" data-sf-ec-immutable=""><strong>GSK-286 (GSK 2556286)</strong></a><sup>b</sup></td>
      <td><a href="https://clinicaltrials.gov/ct2/show/NCT03678688" data-sf-ec-immutable=""><strong>OPC-167832</strong></a><sup>b</sup></td>
      <td>Bedaquiline with two OBRs<sup>c</sup> (all-oral, 9 months; with injectable, 6 months) <a href="https://clinicaltrials.gov/ct2/show/NCT02409290" data-sf-ec-immutable=""><strong>(STREAM Stage 2)</strong></a></td>
    </tr>
    <tr>
      <td><a href="https://clinicaltrials.gov/ct2/show/NCT04890535" data-sf-ec-immutable=""><strong>TBAJ-587</strong></a><sup>b</sup></td>
      <td><a href="https://www.newtbdrugs.org/pipeline/compound/spr720-fobrepodacin" data-sf-ec-immutable=""><strong>SPR720 (Fobrepodacin)</strong></a><sup>b</sup></td>
      <td>Bedaquiline and delamanid with various existing regimens for MDR-TB and XDR-TB <a href="https://clinicaltrials.gov/ct2/show/NCT02754765" data-sf-ec-immutable=""><strong>(endTB trial)</strong></a></td>
    </tr>
    <tr>
      <td><a href="https://clinicaltrials.gov/ct2/show/NCT04493671" data-sf-ec-immutable=""><strong>TBAJ-876</strong></a><sup>b</sup></td>
      <td><a href="https://clinicaltrials.gov/ct2/show/NCT03563599" data-sf-ec-immutable=""><strong>Telacebec-(Q203)</strong></a><sup>b</sup></td>
      <td>Bedaquiline-delamanid-linezolid-clofazimine for fluoroquinolone-resistant MDR-TB <a href="https://clinicaltrials.gov/ct2/show/NCT03896685" data-sf-ec-immutable=""><strong>(endTB-Q)</strong></a></td>
    </tr>
    <tr>
      <td><a href="https://clinicaltrials.gov/ct2/show/NCT04670120" data-sf-ec-immutable=""><strong>TBI-166</strong></a><sup>b</sup></td>
      <td><a href="https://clinicaltrials.gov/ct2/show/NCT04176250" data-sf-ec-immutable=""><strong>TBA-7371</strong></a><sup>b</sup></td>
      <td><strong>Rifampicin</strong><br />
          >High-dose rifampicin and linezolid to reduce mortality among people with TB meningitis (<a href="https://clinicaltrials.gov/ct2/show/NCT04145258" data-sf-ec-immutable=""><strong>INTENSE-TBM</strong></a>)<sup>g</sup><br />
          High-dose rifampicin to shorten drug-susceptible TB treatment (<a href="https://clinicaltrials.gov/ct2/show/NCT04485156" data-sf-ec-immutable=""><strong>Hi-DoRi-3</strong></a>)<br />
          High-dose rifampicin with standard regimen for drug-susceptible TB treatment (<a href="https://clinicaltrials.gov/ct2/show/NCT02581527" data-sf-ec-immutable=""><strong>RIFASHORT</strong></a>)</td>
    </tr>
    <tr>
      <td><a href="https://clinicaltrials.gov/ct2/show/NCT03758612" data-sf-ec-immutable=""><strong>TBI-223</strong></a><sup>b</sup></td>
      <td><strong>Delpazolid</strong><br />
      Delpazolid dosing in combination With bedaquiline, delamanid, and moxifloxacin (<a href="https://clinicaltrials.gov/ct2/show/NCT04550832" data-sf-ec-immutable=""><strong>PanACEA-DECODE-01</strong></a>)<br />
      <a href="https://clinicaltrials.gov/ct2/show/NCT02836483" data-sf-ec-immutable=""><strong>EBA, Safety and PK of delpazolid</strong></a></td>
      <td>Several 2-month regimens for drug-susceptible TB <a href="https://clinicaltrials.gov/ct2/show/NCT03474198" data-sf-ec-immutable=""><strong>(TRUNCATE-TB)</strong></a></td>
    </tr>
    <tr>
      <td>High dose isoniazid for isoniazid-resistant or drug-susceptible TB (<a href="https://actgnetwork.org/studies/a5312-the-early-bactericidal-activity-of-high-dose-or-standard-dose-isoniazid-among-adult-participants-with-isoniazid-resistant-or-drug-sensitive-tuberculosis/" data-sf-ec-immutable=""><strong>ACTG A5312</strong></a>)</td>
      <td><a href="https://clinicaltrials.gov/ct2/show/NCT01785186" data-sf-ec-immutable=""><strong>SQ109</strong></a><sup>b</sup></td>
      <td>Short intensive treatment for children with TB meningitis (6 months of daily rifampicin, isoniazid, pyrazinamide and levofloxacin (<a href="https://www.isrctn.com/ISRCTN40829906" data-sf-ec-immutable=""><strong>SURE</strong></a>)<sup>e,f,g</sup></td>
    </tr>
    <tr>
      <td>&nbsp;</td>
      <td><a href="https://clinicaltrials.gov/ct2/show/NCT03959566" data-sf-ec-immutable=""><strong>Sutezolid</strong></a><sup>b</sup></td>
      <td>Ultra-short treatment for fluoroquinolone sensitive MDR-TB (<a href="https://clinicaltrials.gov/ct2/show/study/NCT03867136" data-sf-ec-immutable=""><strong>TB-TRUST</strong></a>)</td>
    </tr>
    <tr>
      <td>&nbsp;</td>
      <td><a href="https://clinicaltrials.gov/ct2/show/NCT04608955" data-sf-ec-immutable=""><strong>Sudapyridine (WX-081)</strong></a><sup>b</sup></td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>&nbsp;</td>
      <td><strong>Bedaquiline</strong><br />
          PK, safety and tolerability of bedaquiline with OBR <sup>c</sup> in HIV-infected and uninfected children with MDR-TB (<a href="https://clinicaltrials.gov/ct2/show/NCT02906007" data-sf-ec-immutable=""><strong>IMPAACT P1108</strong></a>)<sup>e,f,g</sup><br />
          PK and safety of bedaquiline with OBR <sup>c</sup> in HIV-uninfected children with MDR-TB (<a href="https://clinicaltrials.gov/ct2/show/NCT02354014" data-sf-ec-immutable=""><strong>TMC207-C211</strong></a>)<sup>e,f,g</sup></td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>&nbsp;</td>
      <td><strong>Delamanid</strong><br />
                  PK, safety and tolerability of delamanid with OBR <sup>c</sup> in HIV-infected and uninfected children with MDR-TB (<a href="https://clinicaltrials.gov/ct2/show/NCT03141060" data-sf-ec-immutable=""><strong>IMPAACT 2005</strong></a>)<sup>e,f,g</sup></td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>&nbsp;</td>
      <td><strong>Rifampicin</strong><br />
     High-dose rifampicin for drug-susceptible TB (<a href="https://clinicaltrials.gov/ct2/show/NCT01785186" data-sf-ec-immutable=""><strong>PanACEA-MAMS-TB-01</strong></a>)<br />
     High-dose rifampicin for TB meningitis (<a href="https://clinicaltrials.gov/ct2/show/NCT02169882" data-sf-ec-immutable=""><strong>ReDEFINe</strong></a>)</td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>&nbsp;</td>
      <td><strong>Linezolid</strong><br />
                  Efficacy and tolerability of two doses of linezolid, combined with bedaquiline, delamanid, and clofazimine (<a href="https://clinicaltrials.gov/ct2/show/NCT05007821" data-sf-ec-immutable=""><strong>Linezolid dosing</strong></a>)</td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>&nbsp;</td>
      <td><strong>Clofazimine</strong><br />
                  PK, safety, tolerability and acceptability of child-friendly formulations of clofazimine and moxifloxacin to treat children with RR-TB (<a href="http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45441" data-sf-ec-immutable=""><strong>CATALYST</strong></a>)<sup>e,f,g</sup><br />
                  PK, safety, and acceptability of clofazimine in children with RR-TB <strong>(Clofazimine Kids Study)</strong><sup>e,f,g</sup></td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>&nbsp;</td>
      <td>Bedaquiline and pretomanid with existing and re-purposed anti-TB drugs for MDR-TB (<a href="https://clinicaltrials.gov/ct2/show/NCT02589782" data-sf-ec-immutable=""><strong>TB PRACTECAL Phase II/III trial)</strong></a>)</td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>&nbsp;</td>
      <td>Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine (<a href="https://clinicaltrials.gov/ct2/show/NCT03828201" data-sf-ec-immutable=""><strong>DRAMATIC</strong></a>)<sup>f,g</sup></td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>&nbsp;</td>
      <td>Shorter regimens including clofazimine and rifapentine for drug-susceptible TB (<a href="https://clinicaltrials.gov/ct2/show/NCT04311502" data-sf-ec-immutable=""><strong>CLO-FAST trial/A5362</strong></a>)</td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>&nbsp;</td>
      <td>Pretomanid-containing regimens to shorten treatment for drug-susceptible TB (<a href="https://clinicaltrials.gov/ct2/show/NCT02256696" data-sf-ec-immutable=""><strong>APT trial</strong></a>)</td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>&nbsp;</td>
      <td>Delamanid&ndash;linezolid&ndash;levofloxacin&ndash; pyrazinamide for fluoroquinolone- susceptible MDR-TB (<a href="https://clinicaltrials.gov/ct2/show/NCT02619994" data-sf-ec-immutable=""><span class="tb72s45"><strong>MDR-END trial</strong></a>)</td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>&nbsp;</td>
      <td>Levofloxacin with OBR<sup>c</sup> for MDR-TB (<a href="https://clinicaltrials.gov/ct2/show/NCT01918397" data-sf-ec-immutable=""><strong>Opti-Q</strong></a>)</td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>&nbsp;</td>
      <td>4-month treatment for drug-susceptible TB (<a href="https://clinicaltrials.gov/ct2/show/NCT02821832" data-sf-ec-immutable=""><strong>PredicTB trial</strong></a>)</td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>&nbsp;</td>
      <td><a href="https://clinicaltrials.gov/ct2/show/NCT03882177" data-sf-ec-immutable=""><strong>Pravastatin</strong></a><sup>d</sup></td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>&nbsp;</td>
      <td>><a href="https://clinicaltrials.gov/ct2/show/NCT03891901" data-sf-ec-immutable=""><strong>Imatinib</strong></a><sup>d</sup></td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>&nbsp;</td>
      <td><a href="https://clinicaltrials.gov/ct2/show/NCT04930744" data-sf-ec-immutable=""><strong>Metformin</strong></a><sup>d</sup></td>
      <td>&nbsp;</td>
    </tr>
    <tr>
      <td>&nbsp;</td>
      <td>Multiple adjunctive host-directed TB therapies for drug-susceptible TB (<a href="https://clinicaltrials.gov/ct2/show/NCT02968927" data-sf-ec-immutable=""><strong>(TBHDT)</strong></a>)<sup>d</sup></td>
      <td>&nbsp;</td>
    </tr>
  </tbody>
</table>


<div class="footnote">
Source: Adapted from the Working Group on New TB Drugs pipeline. More information on these products and other ongoing projects can be found at <a href="https://www.newtbdrugs.org/pipeline/clinical" data-sf-ec-immutable="">https://www.newtbdrugs.org/pipeline/clinical</a>.<br />

<sup>a</sup> New drug compounds are listed first, followed by repurposed drugs, treatment regimens, and then host direct therapies. <br />
<sup>b</sup> New chemical entity. <br />
<sup>c</sup> Optimized Background Regimen. <br />
<sup>d</sup> Host directed therapies. <br />
<sup>e</sup> Includes infants (aged &lt;12 months).<br />
<sup>f</sup> Includes children (aged &lt;10 years).<br />
<sup>g</sup> Includes adolescents (aged 10-19 years).

</div>







<h3><span class="red">Table 7.3</span>&nbsp;The global clinical development pipeline for new drugs and drug regimens to treat TB infection, August 2022</h3>


<table class="res_table">
  <tbody>
    <tr>
      <th style="background-color:#92C4E1;">Phase I/II</th>
      <th style="background-color:#3B80A8;">Phase III/IV</th>
    </tr>
    <tr>
      <td><a href="https://clinicaltrials.gov/ct2/show/NCT04272242" target="_blank" data-sf-ec-immutable=""><strong>ACTG-A5372</strong></a><br />
          Drug-drug interactions between rifapentine and dolutegravir in HIV and TB co-infected individuals</td>
      <td><a href="https://clinicaltrials.gov/ct2/show/NCT03568383" target="_blank" data-sf-ec-immutable=""><strong>A5300B/I2003/PHOENIx</strong></a><br />
          Efficacy and safety of 26 weeks of delamanid versus isoniazid to prevent TB among high-risk household contacts of MDR-TB patients</td>
    </tr>
    <tr>
      <td><a href="https://clinicaltrials.gov/ct2/show/NCT03435146" target="_blank" data-sf-ec-immutable=""><strong>DOLPHIN and DOLPHIN TOO</strong></a><br />
          3HP versus standard isoniazid preventive therapy among HIV-infected patients taking dolutegravir-based antiretroviral treatment</td>
      <td><a href="https://clinicaltrials.gov/ct2/show/NCT03785106" target="_blank" data-sf-ec-immutable=""><strong>1HP vs 3HP among people living with HIV</strong></a></td>
    </tr>
    <tr>
      <td><a href="https://clinicaltrials.gov/ct2/show/NCT05122767" target="_blank" data-sf-ec-immutable=""><strong>DOLPHIN KIDS</strong></a><sup>a,b,c</sup><br />
          Study of dolutegravir-based ART and 3HP in children and adolescents living with HIV</td>
      <td><a href="https://clinicaltrials.gov/ct2/show/NCT04600167" target="_blank" data-sf-ec-immutable=""><strong>PROTID</strong></a><br />
          Safety and efficacy of 3HP versus placebo to prevent TB in people with diabetes</td>
    </tr>
    <tr>
      <td><a href="https://clinicaltrials.gov/ct2/show/NCT05122026" target="_blank" data-sf-ec-immutable=""><strong>DOLPHIN Moms</strong></a><br />
          1HP versus 3HP with pharmacokinetics of dolutegravir among pregnant women with HIV</td>
      <td><a href="https://clinicaltrials.gov/ct2/show/NCT04528277" target="_blank" data-sf-ec-immutable=""><strong>SCRIPT-LGTB</strong></a><br />
          Short course rifapentine and isoniazid for the preventive treatment of genital TB</td>
    </tr>
    <tr>
      <td><a href="https://clinicaltrials.gov/ct2/show/NCT02651259" target="_blank" data-sf-ec-immutable=""><strong>IMPAACT P2001</strong></a><br />
          Evaluating pharmacokinetics, tolerability, and safety of rifapentine and isoniazid in pregnant and postpartum women</td>
      <td><a href="https://clinicaltrials.gov/ct2/show/NCT04094012" target="_blank" data-sf-ec-immutable=""><strong>SDR: 1HP vs 3HP</strong></a><br />
          Risk of systemic drug reactions (SDRs) during 3HP versus 1HP administration</td>
    </tr>
    <tr>
      <td><a href="https://clinicaltrials.gov/ct2/show/NCT02771249" target="_blank" data-sf-ec-immutable=""><strong>Impact of 3HP on pharmacokinetics of dolutegravir and darunavir, with cobicistat</strong></a></td>
      <td><a href="https://www.isrctn.com/ISRCTN92634082" target="_blank" data-sf-ec-immutable=""><strong>TB-CHAMP</strong></a><sup>b</sup><br />
          Six months of daily levofloxacin for the prevention of TB among children household contacts of people with MDR-TB</td>
    </tr>
    <tr>
      <td><a href="https://clinicaltrials.gov/ct2/show/NCT02613169" target="_blank" data-sf-ec-immutable=""><strong>iTIPS</strong></a><sup>a</sup><br />
          TB infection prevention study in HIV-exposed uninfected infants</td>
      <td><a href="https://clinicaltrials.gov/ct2/show/NCT03474029" target="_blank" data-sf-ec-immutable=""><strong>TBTC Study 37/ASTERoid, Phase II/III</strong></a><br />
          Safety, tolerability, and effectiveness of 6 weeks of rifapentine to prevent TB infection</td>
    </tr>
    <tr>
      <td><a href="https://clinicaltrials.gov/ct2/show/NCT03730181" target="_blank" data-sf-ec-immutable=""><strong>TBTC Study 35</strong></a><sup>a,b,c</sup><br />
          Dose finding and safety study of rifapentine and isoniazid in HIV-infected and HIV-uninfected children with TB infection</td>
      <td><a href="https://www.chictr.org.cn/showprojen.aspx?proj=30532" target="_blank" data-sf-ec-immutable=""><strong>TPT and rheumatic disease</strong></a><br />
          9H versus 3HP among people with rheumatic disease</td>
    </tr>
    <tr>
      <td><a href="https://clinicaltrials.gov/ct2/show/NCT03988933" target="_blank" data-sf-ec-immutable=""><strong>2R2</strong></a><sup>c</sup><br />
          Higher dose rifampin for 2 months versus standard dose rifampin to treat TB infection</td>
      <td><a href="https://clinicaltrials.gov/ct2/show/NCT04703075" target="_blank" data-sf-ec-immutable=""><strong>Ultra-Curto</strong></a><br />
          1HP versus 3HP among people uninfected with HIV</td>
    </tr>
    <tr>
      <td><a href="https://clinicaltrials.gov/ct2/show/NCT03900858" target="_blank" data-sf-ec-immutable=""><strong>SCRIPT-TB</strong></a><br />
          Short course rifapentine and isoniazid for prevention of TB among people with silicosis</td>
      <td><a href="https://anzctr.org.au/Trial/Registration/TrialReview.aspx?id=369817" target="_blank" data-sf-ec-immutable=""><strong>V-QUIN MDR trial</strong></a><sup>a,b,c</sup><br />
          Six months of daily levofloxacin for the prevention of TB among household contacts of people with MDR-TB</td>
    </tr>
    <tr>
      <td><a href="https://clinicaltrials.gov/ct2/show/NCT03510468" target="_blank" data-sf-ec-immutable=""><strong>YODA</strong></a><br />
          Impact of 3HP on pharmacokinetics of tenofovir alafenamide</td>
      <td><a href="https://clinicaltrials.gov/ct2/show/NCT02980016" target="_blank" data-sf-ec-immutable=""><strong>WHIP3TB</strong></a><br />
          Evaluation of 3HP versus periodic 3HP versus 6H in people living with HIV</td>
    </tr>
  </tbody>
</table>




<h3><span class="red">Table 7.4</span>&nbsp;The global clinical development pipeline for new TB vaccines, August 2022</h3>


<table class="res_table">
  <tbody>
    <tr>
      <th style="background-color:#92C4E1;">Phase I</th>
      <th style="background-color:#4DA8DB;">Phase IIa</th>
      <th style="background-color:#3B80A8;">Phase IIb</th>
      <th style="background-color:#29465C;">Phase III</th>
    </tr>
    <tr>
        <td><a href="https://clinicaltrials.gov/ct2/show/NCT02337270" target="_blank" data-sf-ec-immutable=""><strong>AdHu5Ag85A</strong></a><sup>b</sup><br />McMaster, CanSino</td>
        <td><a href="https://clinicaltrials.gov/ct2/show/NCT03681860" target="_blank" data-sf-ec-immutable=""><strong>ChAdOx185A-MVA85A</strong></a><sup>b,i</sup><br />University of Oxford</td>
        <td><a href="https://clinicaltrials.gov/ct2/show/NCT04152161" target="_blank" data-sf-ec-immutable=""><strong>BCG revaccination to prevent infection</strong></a><sup>c,i</sup><br />Gates MRI</td>
        <td><a href="https://clinicaltrials.gov/ct2/show/NCT04975737" target="_blank" data-sf-ec-immutable=""><strong>GamTBvac</strong></a><sup>d</sup><br />Ministry of Health, Russian Federation</td>
    </tr>
    <tr>
        <td><a href="https://clinicaltrials.gov/ct2/show/NCT03017378" target="_blank" data-sf-ec-immutable=""><strong>TB/FLU-01L</strong></a><sup>b</sup><br />
            <a href="https://clinicaltrials.gov/ct2/show/NCT02501421" target="_blank" data-sf-ec-immutable=""><strong>TB/FLU-04L</strong></a><sup>b</sup><br />RIBSP</td>
        <td><a href="https://clinicaltrials.gov/ct2/show/NCT03806686" target="_blank" data-sf-ec-immutable=""><strong>ID93 + GLA-SE(QTP101)</strong></a><sup>d</sup><br />Quratis<br />U.S. NIH/NIAID</td>
        <td><a href="https://clinicaltrials.gov/ct2/show/NCT02712424" target="_blank" data-sf-ec-immutable=""><strong>DAR-901 booster</strong></a><sup>e,i</sup><br />Dartmouth</td>
        <td><a href="http://www.ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=27411&amp;EncHid=&amp;modid=&amp;compid=%27,%2727411det%27" target="_blank" data-sf-ec-immutable=""><strong>MIP/Immuvac</strong></a><sup>e,h,i</sup><br />ICMR, Cadila Pharmaceuticals</td>
    </tr>
    <tr>
        <td>&nbsp;</td>
        <td><a href="https://clinicaltrials.gov/ct2/show/NCT05284812" target="_blank" data-sf-ec-immutable=""><strong>AEC/BC02</strong></a><sup>d</sup><br />Anhui Zhifei Longcom</td>
        <td><a href="https://clinicaltrials.gov/ct2/show/NCT03512249" target="_blank" data-sf-ec-immutable=""><strong>H56: IC31</strong></a><sup>d</sup><br />SSI, Valneva, IAVI</td>
        <td><a href="https://clinicaltrials.gov/ct2/show/NCT04975178" target="_blank" data-sf-ec-immutable=""><strong>MTBVAC</strong></a><sup>c,g</sup><br />Biofabri, University of Zaragoza, IAVI, TBVI</td>
    </tr>
    <tr>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
        <td><a href="https://clinicaltrials.gov/ct2/show/NCT04556981" target="_blank" data-sf-ec-immutable=""><strong>M72/AS01E</strong></a><sup>d,i</sup><br />GSK, Gates MRI</td>
        <td><a href="http://www.ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=27411&amp;EncHid=&amp;modid=&amp;compid=%27,%2727411det%27" target="_blank" data-sf-ec-immutable=""><strong>VPM1002</strong></a><sup>f,h,i</sup><br />SIIPL, VPM</td>
    </tr>
    <tr>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
        <td><a href="https://clinicaltrials.gov/ct2/show/NCT04919239" target="_blank" data-sf-ec-immutable=""><strong>RUTI</strong></a><sup>&reg;e</sup><br />Archivel Farma, S.L.</td>
        <td><a href="https://clinicaltrials.gov/ct2/show/NCT04453293" target="_blank" data-sf-ec-immutable=""><strong>BCG vaccination to prevent infection (TIPI)</strong></a><sup>c</sup><br />HJF</td>
    </tr>
    <tr>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
        <td>&nbsp;</td>
        <td><a href="https://clinicaltrials.gov/ct2/show/NCT05330884" target="_blank" data-sf-ec-immutable=""><strong>BCG revaccination in children and adolescents (BRiC)</strong></a><sup>c,h,i</sup><br />ICMR</td>
    </tr>
  </tbody>
</table>

<div class="footnote">
<sup>a</sup> Information was self-reported by vaccine sponsors to the Stop TB Partnership Working Group on New TB Vaccines or was identified through clinical trial registries or other public sources of information.<br />
<sup>b</sup> Viral Vector.<br />
<sup>c</sup> Mycobacterial &ndash; Live.<br />
<sup>d</sup> Protein / Adjuvant<br />
<sup>e</sup> Mycobacterial &ndash; Whole Cell or Extract.<br />
<sup>f</sup> Other trials involving VPM1002 include <a href="https://clinicaltrials.gov/ct2/show/NCT04351685" target="_blank" data-sf-ec-immutable="">NCT04351685</a>,
                    <a href="https://clinicaltrials.gov/ct2/show/NCT03152903" target="_blank" data-sf-ec-immutable="">NCT03152903</a>.<br />
<sup>g</sup> Includes infants (aged &lt;12 months).<br />
<sup>h</sup> Includes children (aged &lt;10 years).<br />
<sup>i</sup> Includes adolescents (aged 10-19 years).<br />
</div>


